Literature DB >> 20419305

Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease.

Erik Portelius1, Nenad Bogdanovic, Mikael K Gustavsson, Inga Volkmann, Gunnar Brinkmalm, Henrik Zetterberg, Bengt Winblad, Kaj Blennow.   

Abstract

A proposed key event in the pathogenesis of Alzheimer's disease (AD) is the formation of neurotoxic amyloid beta (Abeta) oligomers and amyloid plaques in specific brain regions that are affected by the disease. The main plaque component is the 42 amino acid isoform of Alphabeta (Abeta1-42), which is thought to initiate plaque formation and AD pathogenesis. Numerous isoforms of Abeta, e.g., Abeta1-42, Abeta1-40 and the 3-pyroglutamate derivate of Abeta3-42 (pGluAbeta3-42), have been detected in the brains of sporadic AD (SAD) and familial AD (FAD) subjects. However, the relative importance of these isoforms in the pathogenesis of AD is not fully understood. Here, we report a detailed study using immunoprecipitation in combination with mass spectrometric analysis to determine the Abeta isoform pattern in the cerebellum, cortex and hippocampus in AD, including subjects with a mutation in the presenilin (M146V) or amyloid precursor protein (KM670/671NL) genes, SAD subjects and non-demented controls. We show that the dominating Abeta isoforms in the three different brain regions analyzed from control, SAD, and FAD are Abeta1-42, pGluAbeta3-42, Abeta4-42 and Abeta1-40 of which Abeta1-42 and Abeta4-42 are the dominant isoforms in the hippocampus and the cortex in all groups analyzed, controls included. No prominent differences in Abeta isoform patterns between FAD and SAD patients were seen, underscoring the similarity in the amyloid pathology of these two disease entities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20419305      PMCID: PMC3568930          DOI: 10.1007/s00401-010-0690-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  40 in total

1.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

2.  Purification and cloning of amyloid precursor protein beta-secretase from human brain.

Authors:  S Sinha; J P Anderson; R Barbour; G S Basi; R Caccavello; D Davis; M Doan; H F Dovey; N Frigon; J Hong; K Jacobson-Croak; N Jewett; P Keim; J Knops; I Lieberburg; M Power; H Tan; G Tatsuno; J Tung; D Schenk; P Seubert; S M Suomensaari; S Wang; D Walker; J Zhao; L McConlogue; V John
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

3.  Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro.

Authors:  C J Pike; M J Overman; C W Cotman
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

Review 4.  The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism.

Authors:  Jie Shen; Raymond J Kelleher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-29       Impact factor: 11.205

5.  Chromosome 14-encoded Alzheimer's disease: genetic and clinicopathological description.

Authors:  M Haltia; M Viitanen; R Sulkava; V Ala-Hurula; M Poyhonen; L Goldfarb; P Brown; E Levy; H Houlden; R Crook
Journal:  Ann Neurol       Date:  1994-09       Impact factor: 10.422

6.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

7.  Generation and regulation of beta-amyloid peptide variants by neurons.

Authors:  G K Gouras; H Xu; J N Jovanovic; J D Buxbaum; R Wang; P Greengard; N R Relkin; S Gandy
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains.

Authors:  Hedvig Welander; Jenny Frånberg; Caroline Graff; Erik Sundström; Bengt Winblad; Lars O Tjernberg
Journal:  J Neurochem       Date:  2009-05-15       Impact factor: 5.372

10.  beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms.

Authors:  C Haass; A Y Hung; M G Schlossmacher; D B Teplow; D J Selkoe
Journal:  J Biol Chem       Date:  1993-02-15       Impact factor: 5.157

View more
  108 in total

1.  β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation.

Authors:  Yan Cai; Kun Xiong; Xue-Mei Zhang; Huaibin Cai; Xue-Gang Luo; Jia-Chun Feng; Richard W Clough; Robert G Struble; Peter R Patrylo; Yaping Chu; Jeffrey H Kordower; Xiao-Xin Yan
Journal:  Eur J Neurosci       Date:  2010-08-18       Impact factor: 3.386

2.  Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.

Authors:  Erik Portelius; Henrik Zetterberg; Robert A Dean; Alexandre Marcil; Philippe Bourgeois; Magdalena Nutu; Ulf Andreasson; Eric Siemers; Kwasi G Mawuenyega; Wendy C Sigurdson; Patrick C May; Steven M Paul; David M Holtzman; Kaj Blennow; Randall J Bateman
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 3.  Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress.

Authors:  Carla Garza-Lombó; Yanahi Posadas; Liliana Quintanar; María E Gonsebatt; Rodrigo Franco
Journal:  Antioxid Redox Signal       Date:  2018-03-28       Impact factor: 8.401

4.  Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid.

Authors:  Adnan Halim; Gunnar Brinkmalm; Ulla Rüetschi; Ann Westman-Brinkmalm; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Göran Larson; Jonas Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-28       Impact factor: 11.205

5.  Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.

Authors:  Jessica L Wittnam; Erik Portelius; Henrik Zetterberg; Mikael K Gustavsson; Stephan Schilling; Birgit Koch; Hans-Ulrich Demuth; Kaj Blennow; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

6.  Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease.

Authors:  Violetta N Pivtoraiko; Eric E Abrahamson; Sue E Leurgans; Steven T DeKosky; Elliott J Mufson; Milos D Ikonomovic
Journal:  Neurobiol Aging       Date:  2014-06-24       Impact factor: 4.673

7.  Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice.

Authors:  Jan Stöhr; Carlo Condello; Joel C Watts; Lillian Bloch; Abby Oehler; Mimi Nick; Stephen J DeArmond; Kurt Giles; William F DeGrado; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

8.  Modulation of Amyloid-β42 Conformation by Small Molecules Through Nonspecific Binding.

Authors:  Chungwen Liang; Sergey N Savinov; Jasna Fejzo; Stephen J Eyles; Jianhan Chen
Journal:  J Chem Theory Comput       Date:  2019-09-04       Impact factor: 6.006

Review 9.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

Review 10.  Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Authors:  Julie Dunys; Audrey Valverde; Frédéric Checler
Journal:  J Biol Chem       Date:  2018-08-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.